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Abstract objectives To determine the improvement in positive predictive value of immunological failure
criteria for identifying virological failure in HIV-infected children on antiretroviral therapy (ART) when
a single targeted viral load measurement is performed in children identiﬁed as having immunological
failure.
methods Analysis of data from children (<16 years at ART initiation) at South African ART sites
at which CD4 count⁄per cent and HIV-RNA monitoring are performed 6-monthly. Immunological
failure was deﬁned according to both WHO 2010 and United States Department of Health and Human
Services (DHHS) 2008 criteria. Conﬁrmed virological failure was deﬁned as HIV-RNA >5000 copies⁄ml
on two consecutive occasions <365 days apart in a child on ART for ‡18 months.
results Among 2798 children on ART for ‡18 months [median (IQR) age 50 (21–84) months at ART
initiation], the cumulative probability of conﬁrmed virological failure by 42 months on ART was 6.3%.
Using targeted viral load after meeting DHHS immunological failure criteria rather than DHHS
immunological failure criteria alone increased positive predictive value from 28% to 82%. Targeted
viral load improved the positive predictive value of WHO 2010 criteria for identifying conﬁrmed
virological failure from 49% to 82%.
conclusion The addition of a single viral load measurement in children identiﬁed as failing immu-
nologically will prevent most switches to second-line treatment in virologically suppressed children.
keywords HIV, virological failure, children, antiretroviral therapy, monitoring, immunological failure
Introduction
In many resource-limited settings, access to HIV-RNA
measurement is limited and clinicians rely on clinical and
immunological criteria to identify children failing ﬁrst-line
antiretroviral therapy (ART). These criteria have poor
diagnostic accuracy for virological failure, with both low
sensitivity and positive predictive value (PPV; Jittamala
et al. 2009; Ruel et al. 2010; Davies et al. 2011). Low PPV
means that children may be inappropriately switched to
limited and expensive second-line ART, when they are still
virologically suppressed. Conﬁrming treatment failure
with a single elevated targeted HIV-RNA measurement
once immunological failure criteria are met [targeted viral
load (TVL) approach], together with a thorough
*The members of IeDEA Southern Africa Collaboration are given
in Appendix.
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line when the virus is likely to still be sensitive to the ﬁrst-
line regimen. This approach is recommended in WHO
2010 pediatric treatment guidelines (Rewari et al. 2010,
WHO 2010). For example, inappropriate switches to
second-line of adults who had TVL performed were far less
common than of those with CD4 monitoring only (12.4%
vs. 46.9%; Sigaloff et al. 2011).
Different CD4 thresholds have been used to deﬁne
immunological failure (IF). For example, the United States
Department of Health and Human Services (DHHS) 2008
guidelines deﬁned children as failing immunologically if
they experienced any of: a conﬁrmed decline of CD4% by
ﬁve percentage points from the previous value or a
return of CD4 count to below the baseline value in child
aged at least 5 years at baseline (National Institutes of
Health, 2008). The WHO 2010 guidelines consider a child
to be failing immunologically if CD4% or CD4 count
declines to <10% or 200 cells⁄mm
3, respectively (children
aged 2–4 years), or CD4 count declines to <100 cells⁄mm
3
(children aged ‡5 years). No deﬁnition of IF is provided for
children <2 years of age (WHO 2010). We have previously
shown that the sensitivity of the DHHS 2008 IF deﬁnition
[27%; 95% conﬁdence interval (CI): 19–35%] was greater
than that of WHO 2010 deﬁnition (5%; 95% CI: 2–9%)
for identifying children with conﬁrmed virological rebound
(Davies et al. 2011; Note: Conﬁrmed virological rebound
was deﬁned as HIV-RNA >5000 copies⁄ml on two con-
secutive occasions <365 days apart in a child on ART for
‡18 months who achieved suppression during the ﬁrst year
on ART). However, PPV was low for both DHHS (20%;
95% CI: 13–26%) and WHO 2010 (42%; 95% CI: 22–
62%) criteria. While these results underline the value of
routine HIV-RNA monitoring, access is likely to remain
limited in the short term in many settings because of
ﬁnancial and logistical constraints (Sigaloff et al. 2011).
Therefore, we aimed to use data from children receiving
ART at South African IeDEA-Southern Africa (IeDEA-SA)
sites, all of which had access to at least 6-monthly CD4 and
HIV-RNA monitoring, to determine to what extent PPV
for identifying virological failure improves when adding
TVL to either DHHS or WHO 2010 IF criteria.
Methods
Data were collected prospectively from ART-naı ¨ve chil-
dren (<16 years at ART start) initiating ‡3 antiretroviral
drugs at South African sites participating in IeDEA-SA
(http://www.iedea-sa.org). Site characteristics have been
described previously (Davies et al. 2009). Each site has
institutional ethical approval to contribute data to IeDEA
analyses. HIV-RNA was measured using Amplicor 1.5
(Roche Diagnostics) or NucliSens EasyQ assays (bio-
Merieux), with good comparability (Stevens et al. 2005).
CD4 measurements were performed using standard dual
platform ﬂow cytometry or the single platform PanLeuc-
ogated method (Glencross et al. 2008).
Conﬁrmed virological failure (CVF) was deﬁned as HIV-
RNA >5000 copies⁄ml on two consecutive occasions
<365 days apart in a child who had been on treatment for
at least 18 months irrespective of whether suppression to
<400 copies⁄ml was achieved in the ﬁrst year on treatment.
IF criteria were as follows: DHHS: a decline of CD4% by
ﬁve percentage points from the previous value, conﬁrmed
at a subsequent measurement within 365 days after the
ﬁrst low value (applicable to a child of any age) or a return
of CD4 count to below the baseline value in child aged at
least 5 years at baseline (National Institutes of Health,
2008). WHO (2010): no deﬁnition for children <2 years;
CD4% <10% or CD4 <200 cells⁄mm
3 (age 2–4 years);
CD4 <100 cells⁄mm
3 (age ‡5 years). For each of these IF
criteria, children were further considered to meet TVL
failure criteria if they met the respective IF criteria and the
next HIV-RNA measurement (within 4 months of meeting
IF criteria) was >5000 copies⁄ml. CD4 results for which
there was no available HIV-RNA measurement within
4 months, which was required to assess TVL, were
excluded from the analysis (1% and <1% of measurements
for DHHS 2008 and WHO 2010 criteria, respectively).
For all failure diagnoses (IF, TVL or CVF), measure-
ments had to be taken during a period when the child was
on treatment and not during a treatment interruption.
Where tests were performed asynchronously, IF, TVL and
CVF diagnoses were carried forward for up to 3 months.
We compared each unique paired TVL and CVF diagnosis
to determine diagnostic accuracy, using robust standard
errors to account for multiple measures per patient. TVL
results for which there was no concurrent CVF diagnosis
after carrying forward results were not evaluated. The last
TVL result before the end of follow-up was excluded to
ensure that sufﬁcient follow-up for a conﬁrmatory low
viral load measurement had been performed. All analyses
were performed using stata 11 (Stata Corporation,
College Station, TX, USA).
Results
Data from 2798 children on ART for ‡18 months were
included. Characteristics at ART initiation were as follows:
median (interquartile range) age 50 (21–84) months; 48%
female; 64% WHO Clinical Stage 3 or 4 and 79% WHO-
deﬁned severe immune suppression. One-third of children
started a protease inhibitor-based ﬁrst-line regimen. The
cumulative probability of CVF by 42 months on ART was
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than DHHS IF criteria alone increased PPV from 28% to
82% and the likelihood ratio of a positive test from 2.08
to 23.89, respectively (Table 1). Among the 19 TVL-
diagnosed false positive cases, 8 (42%) had two HIV-RNA
measurements >400 copies⁄ml but only one >5000 cop-
ies⁄ml, and 11 (58%) had a single elevated HIV-RNA with
resuppression at subsequent measurement.
Using TVL after meeting WHO IF criteria rather than
WHO IF criteria alone increased PPV from 49% to 82%
and the likelihood ratio of a positive test from 5.41 to
25.98, respectively (Table 1). Among the four TVL-
diagnosed false positive cases, three (75%) had two
HIV-RNA measurements >400 copies⁄ml but only one
>5000 copies⁄ml, and one (25%) had a single elevated
HIV-RNA with resuppression at subsequent measure-
ment.
Discussion
These results illustrate that although even the most
sensitive immunological criteria detect only a quarter of
cases of virological failure, the addition of TVL to these
criteria raises PPV and could reduce the number of
switches to second-line treatment in virologically sup-
pressed children. More than 80% of children considered to
be failing therapy according to either DHHS or WHO IF
criteria together with TVL would also meet the criteria for
CVF.
Nevertheless, TVL results in a small but important
number of false positive diagnoses as a proportion of
children resuppress after a single elevated HIV-RNA
measurement. Although children were not considered to be
failing therapy according to any deﬁnition if measurements
were taken during a documented treatment interruption,
we did not have detailed adherence data. It is possible that
these measurements may have been taken during adherence
lapses. Because these data come from programs with
routine HIV-RNA monitoring, the elevated HIV-RNA
measurement may have actually facilitated identiﬁcation of
poor adherence, prompting counselling and intervention
with subsequent resuppression (Wilson et al. 2009). This
adds to the evidence in adults supporting HIV-RNA
measurement as a tool to discriminate between poor
adherence and therapeutic failure (Calmy et al. 2007;
Orrell et al. 2007). Routine HIV-RNA monitoring also
allows early accurate identiﬁcation of virological failure
and consequent switching to second-line, thus preventing
accumulation of resistance mutations, which is not possible
with a more limited TVL approach (Wilson et al. 2009;
Sigaloff et al. 2011). Indeed, modelling studies in children
suggest that annual HIV-RNA monitoring after an ini-
tial screen 6 months after ART start would result in a
77% reduction in time spent with virological failure
compared with no HIV-RNA monitoring (Schneider et al.
2011).
Strengths of this study include the large cohort across
many sites in South Africa with routine access to both CD4
Table 1 Diagnostic accuracy of DHHS and WHO immunological failure (IF) criteria alone and DHHS and WHO IF criteria with targeted
viral load monitoring (TVL) for identifying children with conﬁrmed virological failure (CVF)
DHHS IF
criteria met
DHHS IF criteria met
and next HIV-RNA
‡5000 copies⁄ml
WHO IF
criteria met
WHO IF criteria met and
next HIV-RNA ‡5000
copies⁄ml
Cumulative probability
by 2 years (95% CI)
28.8% (26.0–31.8) 5.8% (4.6–7.3) 2.4% (1.7–3.4) 1.2% (0.8–2.0)
Number of evaluable pairs
of data*
2524 2480 2945 2906
Sensitivity (%) (95% CI) 24 (19–29) 22 (17–27) 4 (2–6) 4 (2–6)
Speciﬁcity (%) (95% CI) 88 (87–90) 99 (99–100) 99 (99–100) 100 (100–100)
PPV (%) (95% CI) 28 (22–35) 82 (74–90) 49 (31–66) 82 (65–99)
NPV (%) (95% CI) 86 (84–88) 87 (85–89) 86 (83–88) 86 (84–88)
Number true positives 98 86 18 18
Number true negatives 1873 2066 2487 2473
Number false negatives 306 309 421 411
Number false positives 247 19 19 4
LR+ 2.08 23.89 5.41 25.98
LR) 0.85 0.79 0.97 0.96
Area under ROC curve 0.563 0.604 0.517 0.520
*Evaluable pairs refers to each unique occasion where a diagnosis according to either IF or IF + TVL criteria can be compared with the
CVF diagnosis. Number of evaluable pairs differs for different deﬁnitions because of different data requirements for each deﬁnition.
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TVL and CVF results available for comparison. Limita-
tions of these routinely collected data include missing
baseline CD4 values in some children, which limited
evaluation of DHHS criteria, work-up bias that may
occur if either the reference (HIV-RNA) or index (CD4
with single HIV-RNA) tests are not applied consistently
(Whiting et al. 2004) or when people switch to a second-
line regimen before immunological failure occurs. The
study was further limited by lack of data with respect to
intercurrent illnesses that should be excluded before
considering a low CD4 count to be indicative of immu-
nological failure (WHO 2010).
We conclude that the addition of targeted viral load to
CD4 monitoring will prevent most switches to second-line
therapy in virologically suppressed children. This is
particularly important to avoid exhausting the limited drug
options for children facing lifelong therapy. Our previous
study demonstrated the low sensitivity of immunological
criteria for identifying virological failure (Davies et al.
2011), and TVL should not replace routine HIV-RNA
monitoring in settings such as South Africa where it is
available or easily achievable. Rather, the introduction of
TVL may be a ﬁrst step towards increasing access to
routine viral load monitoring where this is currently
unavailable.
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